Jaume Alijotas Reig Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca
Research lines Immunobiology and immunopathology of recurrent pregnancy loses and spontaneous loses. Around 2-3% of reproductive-age couples suffer recurrent pregnancy loses. Almost 18% of couples that wish to have children suffer infertility problems. Simultaneously, 2-3% of all pregnant women are diagnosed with spontaneous loses. The expression of HLA molecules, specially type G, the degree of trophoblastic apoptosis, the outsourcing of new neoantigens such as phospholipids, the balance between Th1/Th2/Th3 cytokines, the type and quantity of CD4+CD25+Foxp3+ lymphocytes, the kind and the activity of uterine NK cells (uNK) cells, the presence or absence of blocking antibodies, and other mechanisms play different roles in the achievement of the so-called "tolerant microenvironment" needed to develop a normal pregnancy. Therefore, both autoimmune and alloimmune mechanisms are important. We aim at studying which isolated, and specially associated, anomalies can be identified as risk markers to be able to evaluate possible treatments. IP: Jaume Alijotas Reig Cellular microparticles study in women with and without antiphospholipid antibodies with recurrent pregnancy loses and preeclampsia. Cellular microparticles (CMP) are released depending on the activation and/or the presence of cell apoptosis. They are capable of activating both inflammatory and coagulation pathways. It seems that levels of CMP are higher in healthy pregnant women. A working hypothesis establishes that an increase of CMP levels may be found in recurrent pregnancy loses and preeclampsia. It is thought that their thrombophilic capacity may be higher in those patients with anti-phospholipid antibodies, especially among those with lupus anticoagulant. We want to determine MPC levels in non-pregnant healthy women, pregnant women without previous abnormal obstetric events, women with recurrent pregnancy loses, and women with severe preeclampsia. We are also evaluating whether there are differences related to the presence or absence of antiphospholipid antibodies. Finally, we will also characterize the exact type of CMP (endothelial, platelet-like, leuco-monocyte, and throphoblastic). IP: Jaume Alijotas Reig Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Projects Sulfato de magnesio en pauta continua versus discontinua en la conducta expectante de la preeclampsia grave: ensayo clínico randomizado IP: Anna Suy Franch Collaborators: Jaume Alijotas Reig, Maria del Mar Goya Canino Funding agency: Instituto de Salud Carlos III Funding: 62012.5 Reference: PI11/00388 Duration: 01/01/2012 - 30/06/2016 GLOBE: Gestación Ligada a Obesidad y al Entorno. Estudio longitudinal multicéntrico de factores de riesgo asociados a la obesidad en el embarazo IP: - Collaborators: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Maite Avilés García Funding agency: Instituto de Salud Carlos III Funding: 135883 Reference: PI10/01367 Duration: 01/01/2011 - 31/12/2014 Heparina de Bajo Peso Molecular (HBPM) para la prevención de complicaciones derivadas de la insuficiencia placentaria en las pacientes de riesgo sin trombofilia: estudio multicéntrico randomizado IP: - Collaborators: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Elisa Llurba Olivé, Josep Perapoch López Funding agency: Ministerio Sanidad Funding: 80000 Reference: EC10-205 Duration: 01/01/2011 - 31/12/2016 Envejecimiento endotelial y sus efectos pleiotrópicos sobre procesos inflamatorios, de la respuesta inmune y angiogénesis IP: Francesc Miro Mur Collaborators: Jaume Alijotas Reig, Simon Schwartz Navarro Funding agency: Fundación Invest. Médica Mutua Madrileña Funding: 36000 Reference: FMMA/05/2008 Duration: 24/09/2008 - 23/09/2011 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Next page › Last page »
